Fractures in patients with CKD-diagnosis, treatment, and prevention : a review by members of the European Calcified Tissue Society and the European Renal Association of Nephrology Dialysis and Transplantation
Pimentel, Ana (Centro Hospitalar do Algarve)
Ureña-Torres, Pablo (Université Paris Descartes)
Zillikens, M. Carola (Erasmus Medical Center)
Bover, Jordi (Institut d'Investigació Biomèdica Sant Pau)
Cohen-Solal, Martine (Hôpital Lariboisière)
Universitat Autònoma de Barcelona

Date:	2017
Abstract:	Mineral and bone disease is omnipresent in patients with chronic kidney disease (CKD) and leads to a diverse range of clinical manifestations, including bone pain and fractures. The accumulation of traditional clinical risk factors, in addition to those related to CKD, enhances the risk of comorbidity and mortality. Despite significant advances in understanding bone disease in CKD, most clinical and biochemical targets used in clinical practice remain controversial, resulting in an undermanagement of bone fragility. Vitamin D supplementation is widely used, but only a few studies have shown beneficial effects and a reduced risk of fracture and mortality. The achievement of serum levels of 25-hydroxyvitamin D is recommended for CKD patients to reduce a high parathyroid hormone level, which is associated with skeletal fractures. Optimal control of parathyroid hormone also improves bone mineralization and lowers circulating bone biomarkers such as alkaline phosphatase and cross-linked collagen type I peptide. The potential value of more recent biomarkers such as sclerostin and fibroblast growth factor 23, as surrogates for bone fragility, is an encouraging new direction in clinical research but is far from being firmly established. This article reviews the literature related to the pathophysiological role of various mineral and biochemical factors involved in renal osteodystrophy. To better understand bone fragility in CKD, new information related to the impact of disturbances of mineral metabolism on bone strength is urgently needed. The combined expertise of clinicians from various medical disciplines appears crucial for the most successful prevention of fractures in these patients.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Language:	Anglès
Document:	Article de revisió ; recerca ; Versió publicada
Subject:	CKD-MBD ; Bone ; Bone mineral density ; Calcimimetics ; Calcium ; Dialysis ; Fracture ; Parathyroid hormone ; Phosphate ; Vitamin D
Published in:	Kidney International, Vol. 92 Núm. 6 (december 2017) , p. 1343-1355, ISSN 1523-1755

DOI: 10.1016/j.kint.2017.07.021
PMID: 28964571

13 p, 1.1 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles